A Phase 1 interventional study of HM10560A and Placebo in Healthy, sponsored by Hanmi Pharmaceutical Company Limited. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 54 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-02-07.
Sponsored by Hanmi Pharmaceutical Company Limited · Phase 1, Interventional, and Treatment
Study Design
Objectives
The secondary objectives of the study are as follows:
Hanmi Pharmaceutical Company Limited is the lead sponsor of 188 studies on the registry; 10 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
HM10560A 0.089 mg/kg or Placebo
Drug: HM10560A · Drug: Placebo
HM10560A 0.179 mg/kg or Placebo
Drug: HM10560A · Drug: Placebo
HM10560A 0.357 mg/kg or Placebo
Drug: HM10560A · Drug: Placebo
HM10560A 0.714 mg/kg or Placebo
Drug: HM10560A · Drug: Placebo
Subcutaneously administrate at 0 hour on Day 1
Placebo
Safety
Investigate Safety of HM10560A: * Physical examination, Laboratory test, ECG, Vital sign, Adverse event, Local tolerability
Time frame: 1, 2, 3, 5, 7, 11, 15, 22, 29 day after administration
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hanmi Pharmaceutical Company Limited